CADL Candel Therapeutics
Price Chart
Executive Summary
Candel Therapeutics released updated Phase 2a data for its immunotherapy aglatimagene (CAN-2409) in advanced non-small cell lung cancer (NSCLC), showing 50% of patients survived beyond 24 months despite prior inadequate response to immune checkpoint inhibitors. Median overall survival was 25.4 months in the per-protocol population, approximately double historical benchmarks, with strong biomarker evidence of immune activation. The company plans to initiate a pivotal Phase 3 trial in Q2 2026.
Actionable Insight
The durability of response and survival doubling vs. standard of care significantly de-risks the Phase 3 pathway. With Fast Track status and strong mechanistic validation, CADL is positioned for potential partnership or acquisition interest ahead of Phase 3 initiation. Monitor for upcoming trial design details and potential interim readouts.
Key Facts
- 50% of 46 evaluable NSCLC patients survived beyond 24 months after treatment with aglatimagene plus ICI, up from 39% in prior data cut.
- Median overall survival (mOS) was 25.4 months in per-protocol population, and 21.5 months in patients with progressive disease at baseline — ~2x historical control (9.8–11.8 months).
- 85% of long-term survivors (17/20) had baseline PD-L1 TPS <50%, suggesting ability to convert ICI-resistant tumors.
- Post-treatment biopsies showed increased pro-inflammatory gene expression and TCR repertoire diversity, supporting systemic immune activation.
- FDA has granted Fast Track designation; pivotal Phase 3 trial in non-squamous NSCLC planned for Q2 2026.
Financial Impact
Potential blockbuster-level commercial upside if Phase 3 confirms results, given unmet need in ICI-resistant NSCLC and strong survival tail. No direct financial figures disclosed.
Risk Factors
- Phase 2a data are from a small, non-randomized cohort; results may not replicate in larger, controlled Phase 3 setting.
- Aglatimagene requires intratumoral injection, which may limit scalability and adoption compared to systemic therapies.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257128 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
7d ago
|
Press Release
| $8.42 $8.80 | ▲ +4.51% | ▲ +5.21% | $8.50 (+0.95%) |
|
May 15, 2026
25d ago
|
Press Release
| $7.90 $7.66 | ▼ −3.04% | ▼ −2.39% | $8.50 (+7.59%) |
|
May 14, 2026
26d ago
|
8-K
| $8.91 $8.77 | ▼ −1.57% | ▼ −0.34% | $8.50 (−4.60%) |
|
May 14, 2026
26d ago
|
Press Release
| $8.91 $8.77 | ▼ −1.57% | ▼ −0.34% | $8.50 (−4.60%) |
|
May 4, 2026
5w ago
|
Press Release
| $7.53 $7.67 | ▲ +1.86% | ▲ +1.06% | $8.50 (+12.88%) |
|
Apr 29, 2026
5w ago
|
Press Release
| $6.18 $6.18 | · 0.00% | ▼ −1.02% | $8.50 (+37.54%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $5.17 $5.04 | ▼ −2.51% | ▼ −1.12% | $8.50 (+64.41%) |
|
Mar 12, 2026
12w ago
|
8-K
| $4.98 $4.67 | ▼ −6.22% | ▼ −5.63% | $8.50 (+70.68%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $4.98 $4.67 | ▼ −6.22% | ▼ −5.63% | $8.50 (+70.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access